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Abstract 
Mutations in the PTEN gene are associated with a broad spectrum of disorders, including Cowden 
syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Lhermitte-Duclos disease. 
In addition, PTEN mutations have been described in a few patients with autism spectrum disorders 
and macrocephaly. In this study, we screened the PTEN gene for mutations and deletions in 88 
patients with autism spectrum disorders and macrocephaly (defined as ≥2 SD above the mean). 
Mutation analysis was performed by direct sequencing of all exons and flanking regions, as well as the 
promoter region. Dosage analysis of PTEN was carried out using multiplex ligation-dependent probe 
amplification (MLPA). No partial or whole gene deletions were observed. We identified a de novo 
missense mutation (D326N) in a highly conserved amino acid in a 5 year old boy with autism, mental 
retardation, language delay, extreme macrocephaly (+9.6 SD) and polydactyly of both feet. 
Polydactyly has previously been described in two patients with Lhermitte-Duclos disease and Cowden 
syndrome and is thus likely to be a rare sign of PTEN mutations. Our findings suggest that PTEN 
mutations are a relatively infrequent cause of autism spectrum disorders with macrocephaly. 
Screening of PTEN mutations is warranted in patients with autism and pronounced macrocephaly, 
even in the absence of other features of PTEN-related tumor syndromes. 
 
Keywords: Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, polydactyly, sequence 
analysis, multiplex ligation-dependent probe amplification 
 
 
Introduction 
The phosphatase and tensin homolog (PTEN) gene has been implicated in a family of related tumor 
syndromes with autosomal dominant inheritance and highly variable expression, including Cowden 
syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), and Proteus syndrome. CS is a 
familial cancer syndrome characterized by multiple hamartomas, particularly of the skin, and by a high 
risk for breast, thyroid and endometrial cancers. BRRS is characterized by macrocephaly, 
developmental delay, lipomatosis and pigmented macules of the penis. Proteus syndrome is 
characterized by asymmetrical limb overgrowth, macrocephaly, connective tissue nevi and 
lipomatosis. The common feature of these disorders is a predisposition to hamartomas, and they are 
thus collectively referred to as PTEN hamartoma-tumor syndrome [Zbuk et al., 2006]. Several reports 
have also described PTEN mutations in children with autism spectrum disorders (ASDs), mental 
retardation and macrocephaly [Butler et al., 2005; Delatycki et al., 2003; Goffin et al., 2001; Parisi et 
al., 2001; Zori et al., 1998]. In four cases, the children inherited the PTEN mutation from a parent 
affected with CS or BRRS [Delatycki et al., 2003; Goffin et al., 2001; Parisi et al., 2001; Zori et al., 
1998]. A recent mutation analysis of PTEN in 18 subjects with ASD and macrocephaly found three 
males with previously unidentified germline PTEN mutations [Butler et al., 2005]. 
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The PTEN gene, on 10q23.3, encodes a dual specificity phosphatase that negatively regulates the 
phosphatidylinositol 3-kinase (PI3K)/AKT (protein kinase B) pathway [Waite and Eng, 2002]. Although 
initially discovered as a tumor suppressor, more recent studies have highlighted an important role for 
PTEN in brain development. The PI3K/AKT pathway has been implicated in neuronal survival, neurite 
outgrowth, synaptic plasticity, learning and memory [Chen et al., 2005; Dudek et al., 1997; Jaworski et 
al., 2005; Lin et al., 2001]. Conditional transgenic mice lacking PTEN in the cerebral cortex and 
hippocampus exhibit macrocephaly, neuronal hypertrophy and abnormal dendritic arborization, with 
increased dendritic thickness and spine density [Kwon et al., 2006]. These mice also display abnormal 
social interactions and heightened responses to sensory stimuli, analogous to what is observed in 
autism. 
Autism is a neurodevelopmental syndrome characterized by social deficits, communication 
impairments and restricted and repetitive behaviors and interests, with onset before the age of three 
years. Males are affected four times more frequently than females. Autism has a strong genetic 
component with complex inheritance [Veenstra-Vanderweele et al., 2004]. Monogenic disorders and 
chromosomal abnormalities are identified in at least 10% of patients, but the underlying cause remains 
unknown in the majority of patients. Linkage and association studies have failed to identify any definite 
genes that confer a significant risk for autism [Veenstra-Vanderweele et al., 2004]. It is likely that the 
etiological heterogeneity involved in autism is hindering progress in the identification of susceptibility 
variants, because many of the patients included in these studies, considered to have "idiopathic" 
autism, have in fact monogenic or genomic disorders that have gone undetected. 
Autism is associated with macrocephaly in approximately 20% of cases [Fombonne et al., 1999; 
Miles et al., 2000]. Brain overgrowth is usually not present at birth but develops during childhood 
[Lainhart et al., 1997]. Although macrocephaly is one of the most widely replicated neurobiological 
findings in autism, its pathogenesis remains unknown. The discovery of PTEN mutations in patients 
with ASD and macrocephaly [Butler et al., 2005; Delatycki et al., 2003; Goffin et al., 2001; Parisi et al., 
2001; Zori et al., 1998] suggests that PTEN could be involved in other cases of autism. Thus, the aim 
of this study was to assess the frequency of PTEN mutations in cases of ASD associated with 
macrocephaly, defined as an occipitofrontal head circumference (HC) ≥2 SD above the mean. We 
screened the PTEN gene by direct sequencing in 88 subjects with ASD and macrocephaly. 
Furthermore, as interstitial deletions of the 10q23 region encompassing PTEN and partial gene 
deletions have been identified in individuals with PTEN-related syndromes [Hendriks et al., 2003; 
Marsh et al., 1999; Zhou et al., 2003], we screened for PTEN deletions using multiplex ligation-
dependent probe amplification (MLPA). 
 
Materials and methods 
Patients 
A total of 88 patients with ASD and macrocephaly (HC ≥2 SD) were included in the study. Among 
these, 49 were recruited by the PARIS (Paris Autism Research International Sibpair) study at 
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specialized clinical centers in seven countries (France, Sweden, Norway, Italy, Belgium, Austria, and 
the United States) and 39 were collected by the Mount Sinai School of Medicine and/or the Autism 
Genetic Resource Exchange (AGRE) [Geschwind et al., 2001]. Patients were selected from a larger 
pool of 462 families for which HC measures were available. We studied all subjects with HC ≥2 SD; in 
families with multiple affected subjects with macrocephaly, only one individual per family was included 
in the mutation screening. 
The patients from the PARIS study included 45 males and 4 females from 16 multiplex families 
(with two or more affected siblings) and 33 simplex families (sporadic cases), with a mean age at the 
last evaluation of 10.5 ± 5.8 years (range 3.5-26). All patients were evaluated by experienced 
psychiatrists or child neurologists. Diagnoses were based on clinical evaluation and DSM-IV criteria; in 
addition, patients were assessed with the Autism Diagnostic Interview-Revised (ADI-R) [Lord et al., 
1994] or the Asperger Syndrome Diagnostic Interview [Gillberg et al., 2001]. Forty-five individuals met 
criteria for autism, 2 for pervasive developmental disorder not otherwise specified (PDD-NOS) and 2 
for Asperger syndrome. Thirty-five patients had mental retardation and 22 had limited or no language. 
Laboratory tests to rule-out medical causes of autism included standard karyotyping, fragile X testing, 
and metabolic screening; brain imaging and EEG were performed when possible. Patients diagnosed 
with medical disorders such as fragile X syndrome or chromosomal abnormalities were excluded. 
There were 41 individuals of Caucasian origin, 2 Black, 1 Asian and 5 of mixed ethnicity. 
Thirty-nine patients were recruited by the Seaver Autism Research Center (SARC) at Mount Sinai, 
New York, co-recruited by the SARC and AGRE, or obtained from AGRE. The patients included 31 
males and 8 females from 35 multiplex families and 4 simplex families, with a mean age at the last 
evaluation of 10.5 ± 4.2 years (range 5-24). The ADI-R was used to assess affected subjects. There 
were 35 individuals with autism, 1 with borderline autism, 2 with Asperger syndrome and 1 with PDD-
NOS. Seventeen patients had mental retardation and 16 had limited or no language. Subjects with co-
morbid genetic disorders were excluded. There were 32 individuals of Caucasian origin, 1 Black, 1 
Asian and 5 of mixed/unknown ethnicity. Informed consent was obtained from all families. The study 
was approved by the research ethics boards of the collaborating institutions. 
PTEN mutation analyses 
The 9 exons of the PTEN gene, intron-exon boundaries, the 5' untranslated region and the proximal 
promoter [Zhou et al., 2003] were screened by bidirectional sequencing using standard procedures. 
When variants not described previously were detected, the DNA of parents and siblings was analyzed 
by direct sequencing. Rare variants were also studied in a control sample of 150 Caucasians, 50 
African-Americans, 10 Chinese and 10 Japanese obtained from the Coriell repository. 
PTEN microdeletion analyses 
We performed MLPA of the PTEN gene using a commercially available kit (P105; MRC-Holland, 
Amsterdam, The Netherlands). The kit contains 2 PTEN probes in the promoter, 4 probes in the 3' 
regions of exons 2, 3, 4, and 8, and 3 probes within exons 5, 6 and 7. Electrophoresis of PCR 
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products was performed on an ABI 3730 sequencing platform and the resultant traces were analyzed 
using the software GeneMarker (SoftGenetics, State College, PA, USA). 
 
Results 
PTEN mutation analyses 
Among the 88 patients screened, we identified seven heterozygous variants, four in the promoter 
region and three intragenic variants, including two missense alterations, as detailed in Table I. Two of 
the promoter variants, –1026CA (found in one patient) and –903GA (found in two patients), had 
been described before in control subjects, and were thus assumed to be polymorphisms [Zhou et al., 
2003]. 
A CT promoter variant at –1088, found in a 21-year old male with Asperger syndrome from 
Sweden, has not been described previously and was not detected in 220 controls. Parental samples 
were not available to evaluate the inheritance of this variant. There was no personal or family history 
of skin lesions or malignancies. The absence of the typical manifestations of PTEN-related syndromes 
in this adult patient suggests that this change is a rare variant, but further studies would be needed to 
clarify its significance. 
A –1084CT variant was detected in a girl from a multiplex family of Caucasian origin. This 
alteration had been described previously as a pathogenic mutation, on the basis of its absence among 
186 controls, aberrant migration pattern of the PTEN immunoreactive protein and increased 
phosphorylation of the PTEN target protein AKT in the patient's lymphoblastoid cell lines [Zhou et al., 
2003]. Segregation analysis revealed that the mother, who was reportedly healthy, was heterozygous 
for the –1084CT variant, as were the two sisters of the proband, one of which was also affected with 
autism. The father did not carry the variant. This sequence variant was also found in two out of 150 
Caucasian controls, but was absent in 50 African-American and 20 Asian control samples. This high 
frequency in controls, compared to the estimated incidence of CS of 1:200 000 [Eng, 2003], suggests 
that the –1084CT promoter variant is likely a polymorphism. 
In exon 1, we identified a CG transition (c.66CG), resulting in a previously undescribed amino 
acid substitution, D22E, in a Caucasian boy with autism. The variant was inherited from his healthy 
father and was also present in his autistic sister but not in the mother. Screening of 220 controls 
showed the D22E variant in one Caucasian individual, suggesting that it could be a rare variant. 
An IVS3-9TC variant in intron 3, found in a female with autism, was transmitted by the healthy 
mother from Iran, but was not present in an unaffected brother. This variant was not detected in any of 
the 220 controls. Given the ethnic origin of the mother, this could be a rare variant, not found in our 
controls because they were not geographically-matched. 
Finally, we found a missense variant in exon 8 (c.976GA, D326N) in a boy with autism. The 
substitution was not detected in the unaffected parents, indicating a de novo mutation in the proband. 
To confirm this result, a second DNA extraction from new blood samples was performed for the patient 
and both parents, confirming the initial results. Furthermore, to exclude non-paternity, we genotyped 
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the proband and the parents with a standard panel of 15 highly informative microsatellite markers on 
multiple chromosomes. The results confirmed paternity and maternity. None of the 440 normal control 
chromosomes were found to carry this missense alteration. 
The D326N mutation occurs within the C-terminal C2 domain (Fig. 1a), in an evolutionarily 
conserved residue found in PTEN orthologues from human to Drosophila melanogaster and 
Caenorhabditis elegans (Fig. 1b), implying an important functional role for this residue in the PTEN 
protein. 
 
PTEN microdeletion analyses 
There was no evidence for a deletion or duplication of any portion of the PTEN gene in any of the 
patients screened with MLPA. 
 
Clinical description of the patient with the de novo PTEN mutation (D326N) 
The proband is a 5-year old boy, the only child of healthy parents of Caucasian and African origin. He 
was born after an uneventful pregnancy at 39 weeks gestation by caesarian section for fetal 
macrosomia. There was no history of gestational diabetes. His weight was 5260 g (+4.2 SD) and his 
length was 54 cm (+2.6 SD). HC at birth was unavailable; HC at 20 days was 44 cm (+8 SD). He was 
born with postaxial hexadactyly of both feet, removed surgically. He sat at 6 months and walked at 18 
months. He had delayed cognitive development; he said his first words at 18 months but used three 
word sentences only at 4.6 years. At 20 months, HC was 58.5 cm (+8.7 SD), height was 83.5 cm (+1.1 
SD) and weight was 15.3 kg (+3.5 SD). 
He was assessed at 3 years 9 months for his developmental delay and was diagnosed as having 
autistic disorder and mental retardation according to DSM-IV criteria. He fulfilled ADI-R criteria for 
autism [Lord et al., 1994]. His developmental age was 2.2 years. In the Vineland Adaptive Behavior 
Scales he achieved a level of 2 years for communication, 2.8 years for daily skills, 2.1 years for 
socialization, and 2.5 years for motor skills. Laboratory investigations, including karyotype, FISH for 
15q11-q13, 22q11 and 22q13, fragile X testing, metabolic screening and EEG were normal. A brain 
MRI at 18 months was reported as normal, except for a discrete hypersignal in the posterior 
periventricular white matter. 
When last evaluated at the age of 5 years 4 months, his HC was 63 cm (+9.6 SD), his height was 
114 cm (+1.7 SD) and his weight was 29.3 kg (+6 SD). Besides his large head, he had no other 
dysmorphic facial features. He had two small café au lait spots, in an ankle and an arm, and a 
mongolian blue patch in the lumbosacral area. He had a 1 mm flesh-colored papule on the right 
shoulder, which had appeared recently according to his mother. His dermatological examination was 
otherwise unremarkable. In particular, he had no subcutaneous lipomas and no penile macules. He 
had echolalic speech and frequent unintelligible verbalizations, but he was able to say some clear 
single words and short sentences occasionally. Neurological examination was normal. 
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His family history was significant for the presence of two paternal cousins affected one with autism 
and the other with hyperactivity. There was no history of malignancies. The father's HC was 59.5 cm 
(+1.8 SD) and his height was 187 cm (+2.2 SD). The mother's HC was 56.5 cm (1.2 SD) and her 
height was 162 cm (mean). 
 
Discussion 
PTEN gene mutation screening in 88 unrelated individuals with ASD and macrocephaly revealed one 
de novo missense mutation, D326N in exon 8, in a patient with autism and developmental delay. No 
PTEN deletions were identified in any of the patients. The patient with the PTEN mutation has 
manifestations of both CS and BRRS, including macrocephaly and mental retardation. Other findings 
reported in BRRS and present in our patient include prenatal and postnatal overgrowth, motor delay, 
language and speech delay, and café au lait macules [Parisi et al., 2001]. He did not show other 
manifestations of BRRS such as penile macules, lipomas, hemangiomas, or symptomatic 
gastrointestinal polyps. Clinical assessment showed no evidence of the mucocutaneous lesions 
pathognomonic of CS (trichilemmomas, acral keratoses, and papillomatous lesions). Many of the 
features/complications of CS, including skin lesions and cancers, do not develop until adulthood, 
making it difficult to diagnose this condition in children. Approximately 50% of the cases of CS are 
familial [Eng, 2003]. Thus, a positive family history of malignancies and characteristic skin lesions may 
help orient the diagnosis. 
The significance of the polydactyly observed in our proband is not straightforward. Polydactyly is 
commonly observed in subsaharian populations, and this finding may thus be fortuitous in our patient. 
However, there are some arguments in the literature that indicate that PTEN mutations may be 
associated with distal limb anomalies. Polydactyly has previously been described in two patients with 
PTEN-related syndromes. The first patient is a female with Lhermitte-Duclos disease (dysplastic 
gangliocytoma of the cerebellum), born with postaxial polydactyly in both hands [Bielschowsky and 
Simons, 1930]. Although a PTEN mutation was not diagnosed in this case, adult onset Lhermitte-
Duclos disease is considered pathognomonic of CS [Zbuk et al., 2006]. The second patient is a boy 
with ASD, macrocephaly, and preaxial polydactyly of the right hand, who inherited a PTEN mutation 
from his father, affected with Lhermitte-Duclos disease and CS [Delatycki et al., 2003]. Interestingly, a 
patient with BRRS and autism carrying a PTEN mutation lacked the second toes [Zori et al., 1998]. 
Other distal limb abnormalities, including broad thumbs and halluces [Parisi et al., 2001], and radial 
ray hypoplasia [Reardon et al., 2001], have been described in patients with PTEN mutations. Thus, 
digital abnormalities may be a rare manifestation of PTEN haploinsufficiency. 
Several case reports of patients with PTEN mutations have described the presence of ASDs. Their 
clinical features, together with those of our patient, are summarized in Table II. Zori et al. [Zori et al., 
1998] described a PTEN mutation (R130X) in a mother with CS and her son with BRRS and autistic 
behavior. The same mutation was described in a family in which the father and four of his five children 
had BRRS [Parisi et al., 2001]. They all had cognitive impairment, speech delay and marked 
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macrocephaly (+3.5-5.2 SD); in addition, one of the sons also exhibited autistic behavior. Similarly, 
Goffin et al. [Goffin et al., 2001] reported a mother with CS who transmitted a PTEN mutation to her 
son; the mother had normal cognitive function and social interactions, whereas the son had mental 
retardation and autism. In another family, the father with CS and Lhermitte-Duclos disease transmitted 
a PTEN mutation to his son, who had developmental delay and ASD [Delatycki et al., 2003]. In all 
these cases, the discovery of a mutation in the child was prompted by the diagnosis of CS or BRRS in 
a parent. Except for the patient described by Zori and colleagues [Zori et al., 1998], none of the other 
children with autism fulfilled diagnostic criteria for any of the PTEN-related syndromes, reflecting the 
age-related penetrance and the variable expression of PTEN mutations. A recent mutation screening 
of PTEN in 18 subjects with ASD and macrocephaly identified three males carrying germline PTEN 
missense mutations [Butler et al., 2005]. The patients had pronounced macrocephalies (+4.5-8 SD), 
and except for one patient with freckles on the penis, no other clinical findings associated with PTEN-
related disorders were noted. Although all the patients with autism and PTEN mutations described so 
far were macrocephalic, it should be noted that macrocephaly is not a universal finding in PTEN 
hamartoma-tumor syndromes. Macrocephaly is observed in only 38% of patients with CS [Eng, 2003], 
but it is the most consistent finding in BRRS, frequently associated with developmental delay 
[Hendriks et al., 2003; Parisi et al., 2001]. Notably, the 8 patients with PTEN mutations and ASD 
identified so far are all males, similar to the male preponderance observed in idiopathic autism. 
Our results suggest that PTEN mutations are a relatively rare cause of autism. For this study, we 
selected among the subjects of the PARIS study and the Mount Sinai datasets with HC measures 
(n=462 families), all the patients with HC ≥2 SD (n=88). The proband with the PTEN mutation had the 
largest HC (+9.6 SD) among all the study subjects. Of the other 87 patients screened, 68 had a HC 
between +2 and +2.9 SD, 18 had a HC between +3 and +4 SD, and only one subject had a HC >+4 
SD. This is in agreement with previous findings indicating that the macrocephaly commonly observed 
in autism is moderate [Miles et al., 2000]. This might explain why the mutation rate in our study (1 in 
88) is much lower than that reported recently by Butler et al. [Butler et al., 2005], who found three 
PTEN mutations among 18 patients with ASD and macrocephaly. In their study, six subjects had a HC 
greater than +4 SD, including the three subjects carrying PTEN mutations. These data suggest that 
the likelihood of identifying PTEN mutations is higher in individuals with marked macrocephaly. Our 
findings also indicate that although PTEN can play a role in rare cases of autism and pronounced 
macrocephaly, it doesn't appear to be involved in the abnormal regulation of brain growth seen in 
about 20% of patients with autism that present macrocephaly [Fombonne et al., 1999; Miles et al., 
2000]. Several other syndromes associated with macrocephaly carry an increased risk for the 
development of autism (Table III), including fragile X syndrome [Hagerman, 2006], Sotos syndrome 
[Morrow et al., 1990; Zappella, 1990], neurofibromatosis type I [Williams and Hersh, 1998], and 22q13 
deletions [Manning et al., 2004], but they too account for only a small number of patients with autism 
and macrocephaly. 
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Interestingly, the patient with the PTEN mutation reported in this study had a father with a large 
head (+1.8 SD), even though the mutation appeared de novo in the child. Similarly, another patient 
with a de novo PTEN mutation and autism had a father with macrocephaly [Butler et al., 2005], while 
an individual with Bannayan-Riley-Ruvalcaba syndrome and autism, who inherited the PTEN mutation 
from his mother, also had a macrocephalic father [Zori et al., 1998] (see Table II). These findings 
suggest that other factors, independent of PTEN, are also involved in the cases of familial 
macrocephaly. Indeed, familial macrocephaly appears to be a common finding in autism, present in 
45%-62% of the parents of the macrocephalic subjects and in 37% of the normocephalic probands 
[Miles et al., 2000; Stevenson et al., 1997]. Macrocephaly has also been shown to be highly familial in 
non-autistic populations [Weaver and Christian, 1980]. 
The D326 residue mutated in our patient lies within the C2 domain, implicated in phospholipid 
membrane binding [Lee et al., 1999] and the regulation of cell migration [Raftopoulou et al., 2004]. The 
C2 domain recruits PTEN to the membrane and helps orient the catalytic domain appropriately to 
facilitate interaction with the membrane bound substrate [Georgescu et al., 2000]. The D326 residue is 
involved in the hydrogen bond network that forms the phosphatase-C2 interface [Lee et al., 1999]. The 
16 interface residues are among the best conserved across species and the majority have been found 
mutated in cancer [Lee et al., 1999]. Therefore, the c.976GA transition observed in our patient is 
likely to disrupt PTEN function. Previous in vitro studies show that 90% of PTEN missense mutations, 
including several in the C2 domain, eliminate or reduce lipid-phosphatase activity, without affecting the 
ability of the protein to bind to the plasma membrane [Han et al., 2000]. 
Although our study implicates PTEN as an etiological factor in autism and macrocephaly, the 
nature of the underlying cellular events is largely unknown. In mice, the PTEN null mutation is lethal in 
the embryonic stage. Conditional knockout mice with selective inactivation of Pten in limited 
populations of hippocampal and cerebral cortex neurons display behavioral abnormalities reminiscent 
of autism, including decreased social interactions, exaggerated reaction to sensory stimuli, anxiety-like 
behaviors, seizures and decreased learning [Kwon et al., 2006]. Pten mutant mice also exhibit 
progressive macrocephaly, with increased soma size, axonal and dendritic hypertrophy, and increased 
spine density [Kwon et al., 2006]. These findings are particularly interesting in view of previous studies 
showing abnormal development of dendritic spines in various neurodevelopmental disorders 
associated with autism, including fragile X syndrome, Rett syndrome, Angelman syndrome, tuberous 
sclerosis, Down syndrome, and William's syndrome [Ethell and Pasquale, 2005; Fiala et al., 2002]. 
The major substrate of the lipid phosphatase activity of PTEN is phosphatidylinositol-3,4,5 
triphosphate (PIP3). By dephosphorylating PIP3, PTEN opposes the action of PI3K, inhibiting the 
phosphorylation of AKT. Inactivation of PTEN results in increased levels of phosphorylated AKT, 
promoting cell growth, proliferation, survival and migration through multiple downstream effectors 
[Rodgers and Theibert, 2002]. PI3K and AKT have been shown to regulate dendritic arborization in 
neurons through the mammalian target of rapamycin (mTOR) signaling pathway [Jaworski et al., 
2005]. AKT is an important negative regulator of the tuberous sclerosis complex gene products TSC1 
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and TSC2. Interestingly, mutations in TSC1 or TSC2 cause tuberous sclerosis, a neurocutaneous 
disorder associated with an increased risk for autism [Curatolo et al., 2004]. 
Through its protein phosphatase activity, PTEN dephosphorylates the signaling and scaffolding 
protein focal adhesion kinase (FAK) and the adapter protein Shc to inhibit cell migration and formation 
of focal adhesions induced by integrins and growth factors [Gu et al., 1999; Tamura et al., 1998]. 
Thus, PTEN could also alter cell adhesion and migration in the brain through similar mechanisms. 
FAK regulates dendrite outgrowth in developing neurons [Beggs et al., 2003] and controls extension 
and pruning of axons [Rico et al., 2004] through activation of Rho GTPases and assembly of actin 
filaments. Actin cytoskeleton dynamics play an essential role in the regulation of dendritic spine 
morphology and cognitive functions, as indicated by reports of mutations in several X-linked genes 
encoding components of the Rho family signaling pathway in families with mental retardation [Ethell 
and Pasquale, 2005].  
In conclusion, the present findings confirm PTEN mutations as a cause of autism and 
macrocephaly, adding to the increasing list of single gene disorders underlying the developmental 
pathology of ASDs. Our results suggest that patients with autism and pronounced macrocephaly (≥4 
SD) should be screened for PTEN mutations, even in the absence of other features of CS or BRRS. 
Ideally, PTEN screening should also be performed in patients with HC between +3 and +4 SD, but 
given the limited number of mutations in this category, molecular screening may be restricted to 
patients with personal or family history of features pointing to PTEN hamartoma-tumor syndrome. 
Furthermore, we suggest that polydactyly or oligodactyly may be considered uncommon 
manifestations of PTEN mutations. Because the diagnosis of a PTEN mutation implies a significant 
risk for malignancy, patients should be screened regularly for PTEN-related tumors. In addition, 
relatives should be offered genetic counseling, carrier detection and, if positive, oncologic surveillance. 
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Figure 1 (a) Exon/intron structure of the PTEN gene, with main functional domains and mutations 
described in patients with autism spectrum disorder reported previously [Butler et al., 2005; Delatycki 
et al., 2003; Goffin et al., 2001; Parisi et al., 2001; Zori et al., 1998]; the mutation identified in the 
present study (D326N) is indicated in bold. Noncoding sequences in exons 1 and 9 are indicated in 
gray. (b) Alignment of the PTEN gene with homologous genes of other species shows the 
conservation of residue D326 in exon 8 implicated in our patient. Amino acids that are not conserved 
are shaded in grey. 
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TABLE I. Sequence variants identified in the PTEN gene in 88 patients with autism and macrocephaly 
Location and Protein Frequency Head Inheritance Siblings Controls (n=220) 
Nucleotide Change Change  circumference 
Promoter/5’UTR 
 –1088CT … 1 +2.5 SD NA NA 0 
 –1084CT1 … 1 +2.2 SD Maternal present in 1 sib with autism and 1 unaffected sib 2 
 –1026CA2 … 1 +3.5 SD Maternal present in 1 unaffected sib 5 
 –903GA2 … 2 +2.6, +9.6 SD3 ND ND ND 
Exon 1 
 c.66CG D22E 1 +2.1 SD Paternal present in 1 sib with autism 1 
Intron 3 
 IVS3-9TC … 1 +2.2 SD Maternal absent in 1 unaffected sib 0 
Exon 8 
 c.976GA D326N 1 +9.6 SD3 de novo no siblings 0 
1 Described initially as a pathogenic mutation [Zhou et al., 2003] and then as a "variant of unknown significance" [Sarquis et al., 2006] 
2 Described elsewhere as a polymorphism [Zhou et al., 2003] or a "variant of unknown significance" [Sarquis et al., 2006] 
3 The patient with the de novo c.976GA mutation in exon 8 and the largest head circumference (+9.6 SD) of all the study group, also had a 903GA variant 
in the promoter. 
NA= DNA not available for analysis; ND= not determined 
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TABLE II. Clinical findings in our patient and in other patients with autism spectrum disorders carrying PTEN mutations described in the literature 
Clinical finding Present case Zori et al., 1998 Parisi et al., 2001 Goffin et al., 2001 Delatycki et al., 2003  Butler et al., 2005 
 _______________________________________________ 
      Patient 1 Patient 2 Patient 3 
Sex male male male male male male male male 
Age (y) 5 11 8 9 4 4 3.5 2.5 
Neonatal 
Birth weight (g) 5260 (+4.2 SD) 3430 (50th centile) ? 3000 (50th centile) 3160 (20th centile) 4100 (90th centile) 5000 (+3SD) 3400 (97th centile) 
Birth length (cm) 54 (+2.6 SD) ? 90-97th centile 49 (50th centile) 49.5 (50th centile) ? ? 53.8 (95th centile) 
Head circumference 44 (+8 SD) ? 90-97th centile 34 (50th centile) 36 (50th centile) ? "large head" ? 
Macrocephaly (cm) 63 (+9.6 SD) 59 (+3.7 SD) 58.8 (+4.6 SD) 59.9 (+5.2 SD) 59.3 (+7 SD) 62 (+8 SD) 61.1 (+7 SD) 56.5 (+4.5 SD) 
Height (cm) 114 (+1.7 SD) normal 95th centile 139 (+1.7 SD) 107 (80th centile) 109.8 (90th centile) ? 96 (97th centile) 
Weight (kg) 29.3 (+6 SD) normal 95th centile 34.1 (+1.7 SD) 18 (75th centile) 27.4 (+4 SD) ? ? 
Neurological 
Hypotonia —  ?  ? —  — 
ASD autism autistic behavior autistic behavior autism ASD autism autism autism 
Mental retardation      ?   
Motor delay      ?  ? 
Speech delay        ? 
Seizures — — — — — — — possible 
MRI/CT normal normal ND normal venous angioma marked dilatation normal normal 
     in frontal lobe, dilated of perivascular 
     perivascular spaces spaces 
Hands/feet bilateral feet lacked 2nd toes — — preaxial polydactyly — — — 
 polydactyly    of the right hand 
Skin 
Hyperpigmented lesions 2 café au lait spots, multiple nevi — — 1 café au lait spot, — — — 
 mongolian blue patch    mongolian blue patch 
Lipomas — — 1 lipoma in the back — — — — — 
Penile macules —   — — — —  
Gastrointestinal polyps — rectal polyps — — — — — — 
Thyroid disease — goiter and thyroid — — — — — — 
  carcinoma at 18 y 
Other — inguinal hernias downslanting scrotal tongue, wormian bones epicanthal folds, joint laxity, high arched palate, 
   palpebral fissures open ductus Botallis,  flattened nasal bilateral plantar long ears 
    pulmonary valvular  bridge creases,  
    stenosis   hydroceles  
PTEN mutation D326N R130X R130X Y178X c.177-179delA H93R D252G F241S 
 Inheritance de novo maternal paternal maternal paternal de novo ? (father not tested) ? 
Familial macrocephaly — maternal (CS) paternal (BRRS) maternal (CS) paternal (CS+LDD) paternal paternal ? 
  and paternal and 3 affected sibs 
ASD, Autism spectrum disorder; BRRS, Bannayan-Riley-Ruvalcaba syndrome; CD, Cowden syndrome; LDD, Lhermitte-Duclos disease; ND, not done 
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TABLE III. Syndromes with macrocephaly sometimes associated with autism spectrum disorders 
Syndrome Gene Chromosome References 
Sotos syndrome NSD1 5q35 Morrow et al., 1990 
   Zappella, 1990 
Fragile X syndrome FMR1 Xq27.3 Hagerman, 2006 
Neurofibromatosis type 1 NF1 17q11.2 Williams and Hersh, 1998 
Terminal 22q deletion syndrome SHANK3 22q13 Manning et al., 2004 
PTEN hamartoma tumor syndrome1 PTEN 10q23.31 Butler et al., 2005 
   Delatycki et al., 2003 
   Goffin et al., 2001 
   Parisi et al., 2001 
   Zori et al., 1998 
Cole-Hughes syndrome ? ? Naqvi et al., 2000 
Orstavik syndrome2 ? ? Orstavik et al., 1997 
   Steiner et al., 2003 
1 The PTEN hamartoma-tumor syndrome includes Cowden syndrome, Bannayan-Riley-Ruvalcaba 
syndrome, Proteus syndrome, and Lhermitte-Duclos disease. 
2 The Orstavik syndrome was described by Orstavik et al. [Orstavik et al., 1997] and is characterized 
by macrocephaly, epilepsy, autism, mental retardation and dysmorphic features. 
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